SNPMiner Trials (Home Page)
Report for Mutation G106R
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 Evaluate the Safety and Effectiveness of 3T MRI Compatible and Long-term LFP Recordable Deep Brain Stimulation on PD Patients
Deep Brain Stimulation represents the golden standard for surgical treatment of Parkinson's disease (PD), but it is not optimally effective for controlling every motor sign and adverse events are not so infrequent. Therefore,other approaches should be considered. New Approaches in MRI at 3T and long-term local field potential (LFP) recording are very important to target subthalamic nucleus (STN) and understand mechanisms of DBS on Parkinson Patients. This study aims at evaluating the safety and effectiveness of 3T MRI Compatible and LFP recordable deep brain stimulation on PD patients. The Chronically LFP recording using G106R is for two goals: 1) Evaluate the performance of long-term recordable neural simulation. 2) Study long-term clinical and electrophysiology effects of deep brain stimulation on STN.
NCT02937727 Idiopathic Parkinson Patients Device: 3T MRI compatible and LFP recordable G106R of Beijing Pins medical.
The Chronically LFP recording using G106R is for two goals: 1) Evaluate the performance of long-term recordable neural simulation. --- G106R ---
Local Field Potential Recordings using G106R. --- G106R ---
Primary Outcomes
Measure: UPDRS part III Time: 1 month,3 months, 6 months and 12monthsMeasure: Local Field Potential Recordings using G106R Time: 1 month,3 months, 6 months and 12months
Secondary Outcomes
Measure: UPDRS part III Time: 1, 3 months of stimulationMeasure: UPDRS part II Time: 1, 3 months stimulation
Description: Drug Therapy are definied as levodopa equivalent dose,which is devodopa containing or dopamine agonist containing medications
Measure: Levodopa Equivalent Dose Time: 1, 3 months stimulationMeasure: Local Field Potential Recordings using G106R Time: 1 month, 3 months